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Abstract
Background: The WHO recommends that adults with uncomplicated P. falciparum successfully
treated with a blood schizonticide receive a single dose of primaquine (PQ) 45 mg as a
gametocytocidal agent. An earlier pilot study suggested that 75 mg of bulaquine (BQ), of which PQ
is a major metabolite, may be a useful alternate to PQ.
Methods: In a randomized, partial blind study, 90 hospitalized adults with Plasmodium falciparum
malaria that was blood schizonticide-responsive and a gametocytemia of > 55/µl within 3 days of
diagnosis were randomized to receive single doses of either PQ 45 mg or BQ 75 mg on day 4. We
assessed gametocytemia on days 8, 15, 22 and 29 and gametocyte viability as determined by
exflagellation (2° end point) on day 8.
Results: On day 8, 20/31 (65%) primaquine recipients versus 19/59 (32%) bulaquine recipients
showed persistence of gametocytes (P = 0.002). At day 15 and beyond, all patients were
gametocyte free. On day 8, 16/31 PQ and 7/59 BQ volunteers showed gametocyte viability (p =
0.000065).
Conclusion: BQ is a safe, useful alternate to PQ as a Plasmodium falciparum gametocytocidal agent
and may clear gametocytemia faster than PQ.
Introduction
Malaria remains the most important parasitic infection
with 300–500 million people affected yearly and 1.5–2.7
million deaths each year. World over, malaria control has
focused on pharmacological intervention, vector control,
curtailing irrational and indiscriminate use of antimalar-
ials, and the development of vaccines. Of these strategies,
pharmacological intervention remains the most effective
way to combat malaria [1]
Published: 01 February 2006
BMC Infectious Diseases 2006, 6:16 doi:10.1186/1471-2334-6-16
Received: 17 May 2005
Accepted: 01 February 2006
This article is available from: http://www.biomedcentral.com/1471-2334/6/16
© 2006 Gogtay et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2006, 6:16 http://www.biomedcentral.com/1471-2334/6/16
Page 2 of 4
(page number not for citation purposes)
8 aminoquinolines like primaquine are unique antimalar-
ials in that they exhibit activity against multiple life cycle
stages of Plasmodia that infect humans [2]. Primaquine 45
mg as a single dose is recommended by the World Health
Organization (WHO) and the National Antimalarial Pro-
gramme (NAMP) of India for its gametocytocidal activity
in P. falciparum. [2] In 1998, Gogtay et al found that the
efficacy of PQ 45 mg as a falciparum gametocytocidal
agent in patients sensitive to chloroquine in India to be
approximately 77% at Day 29 follow up. [3] During the
past several years, attempts have been made to produce
primaquine analogs with improved anti-malarial activity
and lower toxicity. Bulaquine, formerly called CDRI 80/
53, is metabolized to PQ and differs from PQ only by the
2,4 dihydrofuran group present in the basic side chain
anchored onto the quinoline nucleus in the 8 position [4-
6]. Bulaquine is currently licensed only for use in India for
the radical cure of vivax malaria dosed at 25 mg/day for 5
days, but not as a gametocytocidal agent IN Plasmodium
falciparum. The results of a pilot study by our group
assessing the P. falciparum gametocytocidal effect of a sin-
gle dose of bulaquine 75 mg in India suggested it may be
more effective than PQ 45 mg. [7] Here, in a larger popu-
lation of adults with P falciparum malaria successfully
treated with blood schizonticides, we compared the game-
tocytodical activity of BQ and PQ.
Volunteers and methods
Protocol
The protocol was approved by the institutional ethics
committee and the Drugs Controller General of India. The
study was conducted between January 2002 and April
2004.
Enrollment and procedures
Patients who were at least 16 years old with uncompli-
cated Plasmodium falciparum infection, provided written
informed consent, and had a gametocyte count > 55/µl
within 72 hours of diagnosis, regardless of asexual para-
site counts, were eligible for enrollment. The minimal
gametocyte count was chosen based on infectivity to mos-
quitoes [8]. Patients who were pregnant or lactating, had
received antimalarial treatment in the previous 2 weeks,
had co-infection with Plasmodium vivax, claimed an allergy
to primaquine or bulaquine, or were G6PD deficient were
excluded. On admission, patients were initially assessed
by thick and thin blood films stained using the Jaswant
Singh and Bhattacharji (JSB) field stain [9]. Subsequently,
Giemsa stained blood smears were used to determine the
number of asexual and sexual parasites/µl, assuming a
white blood cell count of 8000/µl.
Enrolled patients were admitted to hospital on Day 1 and
treated under observation with quinine orally 10 mg/kg/
day thrice daily for a total of 7 days and doxycycline 100
mg once daily for 7 days. At day 4, consecutive patients
were randomly allocated in a 1:2 fashion to receive an
observed single dose of either PQ 45 mg or bulaquine 75
mg, based on a computer generated randomization code.
Unequal allocation was used because of earlier studies
suggesting the superiority of bulaquine. The test articles
were administered on day 4 because the incidence of nau-
sea and vomiting is higher in the first few days of schizon-
ticidal therapy and this was given regardless of parasite
clearance. on day 8, all patients were assessed for gameto-
cytemia, discharged, and asked to follow up on days 15,
22, and 29 for further safety and parasitologic checks.
Giemsa stained malaria blood smears during hospitaliza-
tion were done twice a day for the first 72 hours and once
a day thereafter until discharge and on the follow-up days.
The slide readers were blinded to the treatment.
Outcomes
Efficacy was assessed by gametocytemia (primary end
point) and gametocyte viability (secondary end point) on
admission and all follow up days. The latter was assessed
by the modified Shute's technique [10]. This technique
depicts exflagellating microgametes in blood films that
have been kept moist at 21–25°C for 1 hour with com-
plete RPMI medium and AB positive serum and then
Giemsa stained. One or more exflagellating microgametes
was considered a positive test. These end points were iden-
tical to the previous study. [7]
Safety was monitored by routine clinical hematological
and biochemical laboratories and an electrocardiogram
on days 1 and 8. Adverse event recording was focused only
on nausea, vomiting, and epigastric distress and were
recorded only if not reported on Day 1 or if a symptom
worsened after Day 1.
Sample size and statistical analysis
The estimated sample size was calculated using Casa-
grande's method based on a previous study by Gogtay et
al comparing the two drugs [7]. Assuming a 30% differ-
ence in efficacy on Day 8, at 5% significance and 90%
power, a sample size of 28 patients and 56 patients are
required in the primaquine and bulaquine group, respec-
tively, to demonstrate the superiority of bulaquine. P val-
ues ≤ 0.5 were considered significant.
Results
A total of 93 male patients were enrolled. Women with
malaria are not inclined to get admitted, especially
because of hardships related to hospitalization and super-
vised drug administration. The age of the patients ranged
from 16–72 years: 31.47 ± 11.62 years). There were three
drop outs, two in the Bulaquine arm and one in pri-
maquine arm. These patients did not return for any followBMC Infectious Diseases 2006, 6:16 http://www.biomedcentral.com/1471-2334/6/16
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up visit after discharge from the hospital and were omit-
ted from analysis.
At admission, gametocytaemia between the 2 groups was
similar. At day 8, 20/31 (65%) PQ recipients and 19/59
(32%) BQ recipients had gametocytes on blood smear (p
= 0.002). At days 15, 22, and 29, all patients in both treat-
ment groups were free of gametocytes.
At day 8, 16/31 (52%) PQ recipients and 7/59 (12%) BQ
recipients had viable gametocytes on exflagellation testing
(Table)(p = 0.000065). All patients with viable gameto-
cytes had smear positive gametocytemia.
There were no important clinical hematology or biochem-
ical laboratory values, and all electrocardiograms were
within normal limits.
Discussion
A single dose of 45 mg primaquine is given along with or
after schizonticidal therapy in areas where malaria is
endemic as a transmission blocking strategy and currently
is the only option available for this indication. The
present study carried out in 91 cases of uncomplicated
Plasmodium falciparum malaria assessed the efficacy of
bulaquine, the parent compound of primaquine. given as
a single dose of 75 mg for its gametocytocidal effect. On
day 8 of therapy, fewer patients with bulaquine had game-
tocytes as compared to those who received 45 mg pri-
maquine. This suggests superior efficacy of bulaquine or
its ability to clear gametocytes more rapidly, as all patients
were free of gametocytes by day 15 and beyond.
This clearance of gametocytes completely by Day 15 in
both groups in the present study contrasts with our previ-
ous study with 45 mg primaquine where persistent game-
tocytemia was seen in 23% patients responsive to
chloroquine up to Day 29. [3] This may in part be due to
use of different schizonticidal agents in the two studies,
with chloroquine being used in the former and quinine in
the latter, with quinine leading to greater clearance of
asexual parasites.
Based on the results of the present study, bulaquine in a
single dose of 75 mg may represent yet another treatment
option for gametocytocidal effect in addition to pri-
maquine and the current licensing of the drug in the coun-
try could be changed to include gametocytocidal effect
apart from anti-relapse effect. Whether increasing the dose
of primaquine from 45 mg to 60 mg will improve efficacy
needs to be addressed in future studies.
In this study, the Shute technique, which measures the
ability of the male gametocyte to exflagellate was used as
Table 1: Gametocytaemia of patients at different days of follow-up in the two groups
Days of follow-up Primaquine n = 31. Gametocyte density/
µl(mean ± SD)
Bulaquine n = 59. Gametocyte density/µl(mean 
± SD)
1 80-6040(1342 ± 182.80) 80-4160(1064.2 ± 182.80)
4 120-8000(1494 ± 385.04) 80-3260(1003.7 ± 118.35)
8 80-2120(543 ± 128.75) 32-1820(161.01 ± 32.76)
15,22,29 Nil Nil
Table 2: Results of Efficacy.
Days of follow -up No of patients positive for gametocytes Patients sample positive for exflagellation
Pts treated with PQ
N = 31
Pts treated with BQ
N = 59
Pts treated with PQ
N = 31
Pts treated with BQ
N = 59
1 31/31
100%
59/59
100%
31/31
100%
59/59
100%
4 31/31
100%
59/59
100%
31/31
100%
59/59
100%
8 20/31 *
65%
19/59 *
32%
16/31 *
52%
7/59 *
12%
15 Nil Nil Nil Nil
22 Nil Nil Nil Nil
29 Nil Nil Nil Nil
* statistically significant P < 0.05
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a surrogate marker for assessing transmission blocking.
Assessment of true gametocytocidal efficacy of any drug
will depend upon demonstration of the ability to block
transmission to mosquitoes. This in turn can be assessed
by only checking for the presence of the oocyst and ooki-
nete in the mosquito midgut [10], not done in the study.
In the first study where we first reported the declining effi-
cacy of primaquine as a gametocytocidal agent, chloro-
quine versus coartemether was studied, since chloroquine
then was (and still remains) the first line therapy for the
country. [3] The results of the study showed a high degree
of chloroquine resistance (> 50%), and we shifted to
using quinine as first line for uncomplicated falciparum
malaria in the hospital, since there are only isolated
reports of quinine resistance in the country. Drugs that
can block the spread of malarial parasites by killing or pre-
venting the transmission or maturation of gametocytes,
represent important tools in malaria control. Supputta-
mongkol et al compared the efficacies of mefloquine-
artesunate and mefloquine-primaquine on the subse-
quent development of gametocytemias. [11] The latter
combination was not found to be effective in either clear-
ance of existing gametocytemias or the prevention of new
gametocytemias. Primaquine has an extremely short half
life, and as such may not be completely able to eliminate
gametocytes and needs to be used with an effective sch-
izonticidal agent. Persistence of gametocytemia is one of
the predictors of treatment failure and use of an effective
anti-malarial drug to eradicate asexual forms will still
remain the most effective means to prevent gameto-
cytemias.
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